Arrowhead Pharmaceuticals (ARWR) - Stock & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US04280A1007

RNA, Medicine, Treatment, Diseases, Pharmaceuticals

Arrowhead Pharmaceuticals, Inc. is a biotech company that focuses on developing innovative medicines to treat complex and often rare diseases. Their pipeline is packed with promising candidates, each targeting a specific unmet medical need.

One of their lead candidates, Plozasiran, is in late-stage clinical trials to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome. Another promising candidate, Zodasiran, is in Phase 2b clinical trials to treat dyslipidemia and hypertriglyceridemia.

The company is also exploring new avenues in liver disease treatment with ARO-PNPLA3, which is in Phase 1 clinical trials for non-alcoholic steatohepatitis. Additionally, they're investigating ARO-RAGE for inflammatory pulmonary conditions and ARO-MUC5AC for muco-obstructive pulmonary diseases, both in Phase 1/2a clinical trials.

Arrowhead Pharmaceuticals is also working on ARO-MMP7 to treat idiopathic pulmonary fibrosis, ARO-DUX4 for facioscapulohumeral muscular dystrophy, and ARO-SOD1 for amyotrophic lateral sclerosis. Furthermore, they're developing ARO-C3 to treat various complement-mediated or associated renal diseases.

Beyond their proprietary pipeline, the company is collaborating with major pharma players on several projects. For instance, they're working with Janssen Pharmaceuticals on JNJ-3989 to treat chronic hepatitis B virus infection. They're also partnering with GlaxoSmithKline on Olpasiran to reduce apolipoprotein A production.

Other collaborations include a Phase 2 clinical trial with GlaxoSmithKline on GSK-4532990 for liver diseases, a Phase 1 clinical trial with Horizon Therapeutics on HZN-457 for uncontrolled gout, and a Phase 3 clinical trial with Takeda Pharmaceutical on Fazirsiran for liver disease associated with alpha-1 antitrypsin deficiency.

Founded in 2003, Arrowhead Pharmaceuticals, Inc. is headquartered in Pasadena, California, and has established itself as a leader in the development of novel RNA-based therapies.

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for Arrowhead Pharmaceuticals (ARWR) - Stock & Dividends

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for Arrowhead Pharmaceuticals (ARWR) - Stock & Dividends

ARWR Stock Overview

Market Cap in USD 3,291m
Sector Healthcare
Industry Biotechnology
GiC SubIndustry Biotechnology
TER 0.00%
IPO / Inception 1993-06-16

ARWR Stock Ratings

Growth 5y -19.7
Fundamental -80.2
Dividend -
Rel. Performance vs Sector -4.07
Analysts 4.13/5
Fair Price Momentum 22.30 USD
Fair Price DCF -

ARWR Dividends

Yield 12m 0.00%
Yield on Cost 5y 0.00%
Dividends CAGR 5y 0.00%
Payout Consistency 0.0%

ARWR Growth Ratios

Growth 12m -27.64%
Growth Correlation 12m -34%
Growth Correlation 3m -17%
CAGR 5y -1.50%
CAGR/Mean DD 5y -0.03
Sharpe Ratio 12m -0.52
Alpha vs SP500 12m -62.75
Beta vs SP500 5y weekly 1.34
ValueRay RSI 68.41
Volatility GJR Garch 1y 68.71%
Price / SMA 50 5.72%
Price / SMA 200 -8.04%
Current Volume 3479.1k
Average Volume 20d 1176.4k

External Links for ARWR Stock

Wall Street JournalBenzingaYahoo Finance
Fund Manager Positions
What is the price of ARWR stocks?
As of June 22, 2024, the stock is trading at USD 25.50 with a total of 3,479,143 shares traded.
Over the past week, the price has changed by -1.32%, over one month by +1.92%, over three months by -9.67% and over the past year by -28.23%.
What are the forecast for ARWR stock price target?
According to ValueRays Forecast Model, ARWR Arrowhead Pharmaceuticals will be worth about 24.9 in June 2025. The stock is currently trading at 25.50. This means that the stock has a potential downside of -2.31%.
Issuer Forecast Upside
Wallstreet Target Price 52.4 106
Analysts Target Price 55.6 118
ValueRay Target Price 24.9 -2.31